Date: 2018-09-20
Type of information: Development agreement
Compound: new drug candidates for atherosclerosis
Company: Celltrion Healthcare (South Korea) Emory University (USA - GA)
Therapeutic area: Cardiovascular diseases
Type agreement: development
Action mechanism:
Disease: atherosclerosis
Details:
- • On September 20, 2018, Celltrion has signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
- ‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output.
- Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement.
- Meanwhile, Celltrion recently announced a plan of launching Bio CDMO (Contract Development and Manufacturing Organization) business, in a bid to pursue open innovation for development of new drugs.
Financial terms:
Latest news:
Is general: Yes
